1. Canada Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
COSCIENS Biopharma Inc.

COSCIENS Biopharma Inc.

CSCI
COSCIENS Biopharma Inc.US flagNASDAQ Global Market
2.72
USD
- -
- -
8.57MMarket Cap

Total Valuation

COSCIENS Biopharma Inc. carries a market capitalization of 8.57M, placing it among publicly traded companies globally. Its enterprise value stands at 7.47M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap8.57M
Enterprise Value7.47M

Share Statistics

COSCIENS Biopharma Inc. currently has 3.17M shares outstanding.

Shares Outstanding3.17M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 1.54, and the price-to-book ratio stands at 2.71.

PE RatioN/A
PS Ratio1.54
PB Ratio2.71
P/TBV Ratio2.05
P/FCF Ratio-0.91
P/OCF Ratio-0.85

Enterprise Valuation

EV / Sales0.79
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

COSCIENS Biopharma Inc. maintains a current ratio of 2.98, meaning it holds 3.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 31.82, indicating elevated leverage, while an interest coverage ratio of -93.70 demonstrates limited ability to service its debt obligations.

Current Ratio2.98
Quick Ratio2.19
Debt / Equity31.82
Debt / EBITDA-0.17
Interest Coverage-93.70

Financial Efficiency

Return on Equity (ROE)-130.36
Return on Assets (ROA)-48.56
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover2.06

Taxes

Income Tax971,000.00
Effective Tax RateN/A

Stock Price Statistics

COSCIENS Biopharma Inc.'s stock has declined approximately -35.08353% over the past 52 weeks. The 50-day moving average sits at 3.46, while the 200-day moving average is 3.18.

Beta (5Y)N/A
52-Week Price Change-35.08353%
50-Day Moving Average3.46
200-Day Moving Average3.18
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, COSCIENS Biopharma Inc. generated 9.44M in revenue and converted that into -18.84M in net income, yielding earnings per share of -6.00. EBITDA reached -12.93M, while operating income came in at -14.41M.

Revenue9.44M
Gross Profit4.42M
Operating Income-14.41M
Pretax Income-17.87M
Net Income-18.84M
EBITDA-12.93M
EBIT-14.41M
Earnings Per Share (EPS)-6.00

Balance Sheet

COSCIENS Biopharma Inc. holds 9.33M in cash and equivalents against 2.26M in total debt, resulting in a net debt position of -9.33M. Total book value stands at 5.37M, with working capital of 10.97M providing operational flexibility.

Cash & Cash Equivalents9.33M
Total Debt2.26M
Net Debt-9.33M
Equity (Book Value)5.37M
Book Value Per Share1.71
Working Capital10.97M

Cash Flow

COSCIENS Biopharma Inc. produced -17.10M in operating cash flow over the past twelve months. After subtracting -1.10M in capital expenditures, free cash flow totaled -18.21M - equivalent to -5.80 per share.

Operating Cash Flow-17.10M
Capital Expenditures-1.10M
Free Cash Flow-18.21M
FCF Per Share-5.80

Margins

COSCIENS Biopharma Inc. operates with a gross margin of 46.84, reflecting its pricing power and cost economics. The operating margin of -152.66 and net profit margin of -199.56 provide insight into operational efficiency.

Gross Margin46.84
Operating Margin-152.66
Pretax Margin-189.27
Profit Margin-199.56
EBITDA Margin-136.95

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield4.79
FCF Yield-110.01

Stock Splits

COSCIENS Biopharma Inc.'s most recent stock split took place on May 3, 2024 with a 4:1 split ratio.

Last Split Date5/3/2024
Split Ratio4:1

Scores

COSCIENS Biopharma Inc. posts an Altman Z-Score of -1.35, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-1.35